TRIM62 is an E3 ubiquitin ligase that functions as both a tumor suppressor and immune regulator. As a RING finger domain-dependent E3 ligase, TRIM62 catalyzes self-ubiquitination in association with E2 enzyme UBE2D2, leading to its proteasomal degradation 1. In antifungal immunity, TRIM62 mediates Lys-27-linked ubiquitination of CARD9 downstream of C-type lectin receptors, activating NF-κB and p38 MAPK pathways 2. TRIM62 acts as a tumor suppressor in multiple cancers, with loss promoting proliferation, invasion, and epithelial-mesenchymal transition through NF-κB pathway activation 3 4. In pancreatic cancer, TRIM62 inhibits tumor progression by promoting c-Myc ubiquitination 5. Additionally, TRIM62 contributes to inflammation-induced muscle atrophy in critically ill patients by activating inflammatory pathways in myocytes 6. The protein localizes to the cytoplasm and plays important roles in inflammatory bowel disease pathogenesis 7. TRIM62's dual functions in immune regulation and tumor suppression make it a significant therapeutic target, with small molecule inhibitors being developed to disrupt its interaction with CARD9 for IBD treatment 2.